LY 392098

Drug Profile

LY 392098

Latest Information Update: 24 Jun 2003

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Neuroprotectants; Nootropics; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Cognition disorders; Major depressive disorder

Most Recent Events

  • 26 Sep 2001 Preclinical development for Depression in USA (Unknown route)
  • 04 Dec 2000 Two studies have been added to the pharmacodynamics section
  • 19 Apr 2000 Preclinical development for Cognition disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top